entertainment -WSS

entertainment

author：focus 2025-10-01 15:39:54 - browse：96

Moderna's mResvia vaccine — The FDA has approved Moderna’s RSV vaccine for older adults. Moderna

The Food and Drug Administration on Friday approved Moderna’s vaccine to protect older adults against respiratory syncytial virus, or RSV, making this the company’s second licensed product.

The Moderna RSV vaccine, which will be marketed under the name mResvia, was approved for adults 60 and older. It is made using the same messenger RNA platform as Moderna’s other licensed product, its Covid-19 vaccine Spikevax.

“The FDA approval of our second product, mResvia, builds on the strength and versatility of our mRNA platform,” Moderna CEO Stéphane Bancel said in a statement.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： When prostate cancer spreads, where it goes matters

WSS

New rules on organ donation and transplantation 'will bring chaos'

FDA official pushes for dedicated emerging pathogens team

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

7 of the most gruesome medical devices in history

Readout LOUD podcast: Live from STAT Breakthrough Summit West

New rules on organ donation and transplantation 'will bring chaos'

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Psychedelics group wrestles with new pharma identity

Wearables generate powerful data but its not useful to doctors, yet

Medicare details structure of new drug price negotiation program

Russian special forces kill a gunman who broke into a private house near Moscow

Psychedelics group wrestles with new pharma identity

A double vaccine crisis is endangering millions of children

Novavax promises a turnaround & Lilly roils the obesity market

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Jerome Adams on the need for new antivirals for Covid

Caitlin Bernard's story shows physicians can't shy from advocacy

explore

AbbVie dramatically boosts its spending on lobbying

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

With measles on the rise, a personal story of a devastating disease

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Organ transplantation is at a crossroads. Major reform is needed

hotspot

explore

knowledge

hotspot